How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

678 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System

populations (prisoners, etc.) will not be eligible to participate in this study. On weight loss drugs (i.e. orilistat (Xenical®), sibutramine (Meridia®), phenylpropanol-amine (Acutrim®)), or similar over-the-counter medications within 3 months of screening. Any surgery within 30 days of screening Those who currently donate blood, platelets, or plasma Any condition that, in the view of the PI or Co-I, places the subject at high risk or poor treatment and study compliance. We will also enroll 36 (...) ). Taking steroids or biologics: corticosteroids (prednisone); methotrexate, infliximib (Remicade®), etaneracept (Enbrel®); anakinra (Kineret®). Those who are currently donating blood, platelets, or plasma at the time of screening. Vulnerable populations (prisoners, etc.) will not be eligible to participate in this study. On weight loss drugs (i.e. orilistat (Xenical®), sibutramine (Meridia®), phenylpropanol-amine (Acutrim®)), or similar over-the-counter medications within 3 months of screening. Any

2017 Clinical Trials

102. Fluorescent Imaging & Methylene Blue: Ureter Study

: Patient who is unable or unwilling to give informed consent Female participant who is pregnant, lactating or planning pregnancy during the course of the trial. Significant renal or hepatic impairment. Any patients with previous allergies to Methylene Blue Any patients at risk of serotonin syndrome, including those taking serotonin reuptake inhibitors (SSRIs) or serotonin reuptake inhibitors (e.g. duloxetine, sibutramine, venlafaxine, clomipramine, imipramine) Patients with glucose-6-phosphate

2017 Clinical Trials

103. Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

of the study Use of weight lowering medications (orlistat, sibutramine, rimonabant, phentermine) Clinically significant GI (Gastro-Intestinal) disease including inflammatory bowel disease, irritable bowel syndrome, celiac disease, dyspepsia, apparent diabetic gastro paresis, diabetic diarrhoea, or surgery of the gastro-intestinal tract (except appendectomy and cholecystectomy) Subjects who are sexually active and have not been surgically sterilised must be informed that they and their partner use a highly

2017 Clinical Trials

104. Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses

requirements for chemotherapy, radiotherapy or hormonal therapy. Participants must be willing to discontinue any use of NSAIDs like aspirin or ibuprofen until the tumor is removed Participants cannot be taking the following medications because of major pharmacokinetic interactions with celecoxib while being enrolled in the study: Abciximab, Argatroban, Bivalirudin, Cilostazol, Dabigatran, Etexilate, Dipyridamole, Fondaparinux, Heparin, Lepirudin, Pemetrexed, Protein C, Rivaroxaban, Sibutramine, Ticlopidine

2017 Clinical Trials

105. Ultrasound Assessment of the Adventitia, Extra-media (EMT) and Veia Jugularis Interna Thickness

, or participation within the last 3 months, in an organised weight loss programme (or within the last 3 months) Current or history of treatment with medications that may cause significant weight gain for at least 3 months before this trial Current use or use within three months before this trial of GLP-1 receptor agonist, pramlintide, sibutramine, orlistat, zonisamide, topiramate, or phentermine Type 1 diabetes Type 2 diabetes treated with glucose-lowering drugs other than metformin Alloplasty in target knee

2017 Clinical Trials

106. Effects of Cinnamon Supplementation on Glucose Metabolism in Patients With Pre-diabetes

or hypersensitivity to any of the ingredients in the test products. Cognitive impairment or any other reason to expect the patient would have difficulty complying with study protocol Excessive alcohol intake defined as greater than 3 units of alcohol per day. Use of weight loss drugs (e.g., lorcaserin [Belviq]; phentermine/topiramate [Qsymia], liraglutide [Saxenda], Xenical [orlistat], Meridia [sibutramine], Acutrim [phenylpropanol-amine], or similar over-the-counter medications) within 3 months of the screening

2017 Clinical Trials

107. SNAP: a population health guide to behavioural risk factors in general practice

appropriate. For a small number of obese patients (BMI >30 or BMI >27 with other diseases) who do not respond, medical or surgical interventions may need to be considered. Drugs that may be added to education and behavioural interventions include orlistat and sibutramine for long term therapy, and phentermine and diethylpropion for short term use only. Small amounts of weight loss or lack of any increase can be viewed as successes with health gains likely. Any changes made must be able to be maintained

2014 The Royal Australian College of General Practitioners

108. Systematic review with meta-analysis: Orlistat reduces weight but its cost?effectiveness remains unclear

, sibutramine and … Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways. Copyright information: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to Read the full text or download the PDF: Subscribe Log in Log

2013 Evidence-Based Nursing

109. Cost-effectiveness of pharmacotherapy to reduce obesity Full Text available with Trip Pro

Study objective This study evaluated the cost-effectiveness of pharmaceutical interventions, versus standard care, for obesity in Australian adults aged 20 years or older. Interventions Pharmaceutical care consisted of either 15mg sibutramine, once daily, or 120mg of orlistat, thrice daily. Patients were allowed one 12-month course of treatment. This was compared with usual care, with no drug treatment. Location/setting Australia/primary care. Methods Analytical approach: The authors used a Markov (...) not take their medication. Weight regain data were from the Sibutramine Trial of Obesity Reduction and Maintenance (STORM) trial for sibutramine and were assumed to be the same for orlistat. It was assumed that none of the weight loss was permanent. Monetary benefit and utility valuations: Health-related quality of life utilities were calculated, for the nine disease states, using disability-adjusted life-year (DALY) weights from an Australian study. Measure of benefit: The DALYs averted were

2011 NHS Economic Evaluation Database.

110. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis

: sulfonylureas, meglitinides, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 analogues, insulins and insulin analogues, alpha-glucosidase inhibitors, and weight-loss agents (orlistat and sibutramine). Outcomes of interest included glycated haemoglobin (HbA 1c ), hypoglycaemia, body weight, quality of life, long-term complications of diabetes, severe adverse events, and mortality. In included trials, the mean baseline glycated haemoglobin ranged from 6.6% to 10

2011 DARE.

111. Obesity and the Older Persons

, exacerbation of gout and sequelae of hypovolaemia (70). Anti-obesity drugs can be classified as fat-absorption altering (orlistat), thermogenesis increasing (ephedrine) and anorectic (sibutramine, topiramate, SSRIs such as sertraline or fluoxetine). They have been found to be safe and effective in younger adults in multiple randomised controlled trials. Currently, however, there is insufficient evidence to recommend the use of anti-obesity agents in the elderly. The Future In terms of weight loss

2011 Australian and New Zealand Society for Geriatric Medicine

113. Management of diabetes

participants with type 2 diabetes, hypertension, MI, asthma and breast cancer. Four RCTs provided data comparing a Protein Sparing Modified Fast (PSMF) with a Low Calorie Diet (LCD) and found no statistically significant differences in HbA1c or weight loss between these two interventions. 107 A systematic review, including 22 studies on pharmacotherapy for weight loss in adults with type 2 diabetes, focused mainly on weight loss and HbA1c data for orlistat (n=2,036 participants), sibutramine (n=296 (...) ) and fluoxetine (n=1,047). 108 Orlistat resulted in a mean pooled effect weight loss of 2.0 kg (95% CI 1.3 to 2.8) associated with a reduction in HbA1c of 0.5% (5.46 mmol/mol) (95% CI 0.3 (3.28) to 0.6 (6.56)) with follow up between 24 and 57 weeks. Sibutramine resulted in mean pooled effect weight loss of 5.1 kg (95% CI 3.2 to 7.0) with no reduction in HbA1c after follow up of 12 to 52 weeks. Fluoxetine resulted in mean pooled effect weight loss of 3.4 kg (95% CI, 1.7 to 5.2) at 8 to 16 weeks, 5.1 kg (95% CI

2010 SIGN

114. Obesity

- release daily dizziness, mild increase in blood pressure and heart rate excreted by kidneys; pregnancy category B; requires blood- pressure monitoring Sibutramine Meridia (Abbott) Approved for weight loss No Inhibition of norepinephrine and serotonin reuptake 5, 10, or 15 mg/day 5% Mild increase in blood pressure and heart rate (rarely more severe), palpitations Pregnancy category C; requires blood- pressure monitoring Orlistat Xenical (Roche); Alli (GlaxoSmithKline) Approved for weight loss No Lipase (...) Organisation, 2011 • Approved for short-term use only; limited data suggest these stimulants may be effective for > 10 years. SibutramineSibutramine is modestly effective in reducing weight, with differing effects on cardiovascular risk and various adverse effect profiles. • Treatment with sibutramine reduced body weight but not blood pressure. • Randomized trials have shown a 5% greater weight reduction in comparison with placebo (but only short-term trials have been carried out; administration

2011 World Gastroenterology Organisation

115. Highlights of the year in Evidence-Based Medicine

as likely to have an x-ray, ultrasound or imaging after seeing a self-employed urologist as opposed to a Staying on the diagnostic theme, we learnt we should not be pooling diagnostic likelihood ratios in . , and Docs suggested women were hitting the pause button on , which sounded very much like the HRT story. On the drug front, we managed to give out 300,000 prescriptions for sibutramine in the . Put me in charge of the drug budget, I’ll show you some cuts. Yet, nearly 1 in 10 prescribed meds were

2011 TrustTheEvidence

116. Evolution of Pharmacological Obesity Treatments: Focus on Adverse Side-Effect Profiles. (Abstract)

(PPA)], excess non-fatal cardiovascular events (sibutramine), and neuro-psychiatric issues (rimonabant; approved in Europe, but not in the USA). This negative experience has helped mould the current drug development and approval process for new anti-obesity drugs. Differences between the US Food and Drug Administration (FDA) and the European Medicines Agency, however, in perceptions of risk-benefit considerations for individual drugs have resulted in discrepancies in approval and/or withdrawal

2016 obesity & metabolism

117. [Acupuncture for treatment of simple obesity and its effect on serum leptin level of the patient]. (Abstract)

(Shenmen, Endocrine, etc. were selected); the patients in the control group were treated with oral administration of sibutramine. The serum leptin level before and after treatment were determined and the therapeutic effect in reducing body weight was assessed.The total effective rate was 88.0% in the acupuncture group and 80. 0% in the control group, with no significant difference between the two groups (P>0.05); after treatment, the serum leptin level in both the two groups decreased significantly (P

2016 Zhongguo zhen jiu = Chinese acupuncture & moxibustion Controlled trial quality: uncertain

118. Analysis of trace amounts of adulterants found in powders/supplements utilizing Raman spectroscopy coupled to direct analyte-probed nanoextraction-nanospray ionization-mass spectrometry Full Text available with Trip Pro

analysis via nanospray of the particulate of interest eliminates time consuming chromatographic techniques prior to mass spectrometry analysis. This coupled technique combines rapid Raman spectroscopy techniques with direct mass spectrometry to confirm the presence of an adulterant. This technique was applied to an FDA supplied test sample, in which sibutramine, phenolphthalein, and melamine were confirmed to be present.

2016 Analytical methods : advancing methods and applications

119. What weight loss treatment options do geriatric patients with overweight and obesity want to consider? Full Text available with Trip Pro

What weight loss treatment options do geriatric patients with overweight and obesity want to consider? Since the 1990s, a number of weight loss medications have been removed from the USA and or European market because of adverse events associated with these medications. These medications include fenfluramine (heart valve thickening), sibutramine (cardiovascular risk) and rimonabant (depression). This history may affect a patient's desire to consider weight loss medications as an option

2016 Obesity science & practice

120. Can social media data lead to earlier detection of drug‐related adverse events? Full Text available with Trip Pro

Can social media data lead to earlier detection of drug‐related adverse events? To compare the patient characteristics and the inter-temporal reporting patterns of adverse events (AEs) for atorvastatin (Lipitor® ) and sibutramine (Meridia® ) in social media ( versus the FDA Adverse Event Reporting System (FAERS).We identified clinically important AEs associated with atorvastatin (muscle pain) and sibutramine (cardiovascular AEs), compared their patterns in social media (...) postings versus FAERS and used Granger causality tests to assess whether social media postings were useful in forecasting FAERS reports.We analyzed 998 and 270 social media postings between 2001 and 2014, 69 003 and 7383 FAERS reports between 1997 and 2014 for atorvastatin and sibutramine, respectively. Social media reporters were younger (atorvastatin: 53.9 vs. 64.0 years, p < 0.001; sibutramine: 36.8 vs. 43.8 years, p < 0.001). Social media reviews contained fewer serious AEs (atorvastatin, pain: 2.5

2016 Pharmacoepidemiology and drug safety

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>